Cryosite (ASX:CTE) Moat Score: 0/10 (As of Jun. 30, 2026)


ASX:CTE Cryosite Ltd ASX:CTE
51 GF Score
Price A$1.25
GF Value A$0.94
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cryosite Moat Score?

Cryosite has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Cryosite has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cryosite might have No Moat - No discernible moat.

Cryosite  (ASX:CTE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cryosite Moat Score Related Terms

ASX:CTE
51GF Score
Cryosite Ltd ASX:CTE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.25 is trading 33% above its estimated GF Value™ of A$0.94. GuruFocus considers Cryosite to be Significantly Overvalued.

Key valuation signals for ASX:CTE:

  • Moat Score: 0
  • GF Value™: A$0.94 vs. price of A$1.25 (33% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score

Get the complete analysis for ASX:CTE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.25
Price
A$0.94
GF Value